BURLINGAME, Calif.--(BUSINESS WIRE)--Genesis Therapeutics, a company pioneering AI technologies to create medicines for patients with severe and unmet medical needs, announced today that Evan Feinberg Ph.D., Genesis Therapeutics CEO and co-founder, will present at the 40th Annual J.P. Morgan Healthcare Conference. Presentation details are:
Date: January 12, 2022
Time: 5:00 PM EST
The presentation will be accessible to registered conference attendees.
About the Genesis Therapeutics
We’re a team of proven drug hunters, deep learning researchers, and software engineers interrogating unexplored chemical space to identify and develop novel candidates for undrugged and underdeveloped targets with the goal of providing new treatments for patients with severe diseases.
Genesis Therapeutics has created the industry's most advanced molecular AI platform by combining 3D structure-aware deep neural networks, new molecular simulation methods, and a massively scalable molecular generation engine. The company’s technology is uniquely able to address previously undruggable and data-poor targets using robust infrastructure that scales the AI platform on the cloud, enabling immense swaths of chemical space to be searched. Genesis Therapeutics’ AI engineering team and medicinal chemists partner closely to execute and continuously strengthen an innovative process for drug discovery and development.
The company is headquartered in Burlingame, CA with a fully integrated laboratory in San Diego. To learn more, visit genesistherapeutics.ai.
